Title
Category
Credits
Event date
Cost
  • LivDerm
  • TME
  • AAPA Category I CME
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • Participation
$0.00
The increasing incidence of atopic dermatitis (AD) and poor recognition of the disease in some patient groups is a public health concern. AD symptoms and its daily management cause significant effects on quality of life for both patients and caregivers. Timely and adequate treatment of AD is essential for helping to promote better long-term outcomes and quality of life and may help prevent the development of other atopic conditions. However, the treatment of AD is a clinical challenge.
  • LivDerm
  • TME
  • AAPA Category I CME
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • Participation
$0.00
Timely and adequate treatment of atopic dermatitis (AD) is essential for helping to promote better long-term outcomes and quality of life. Targeted immunomodulatory agents, based on recent advances in the understanding of AD pathophysiology, represent additional options for long-term control. In particular, Janus kinase (JAK) inhibitors have emerged as a novel mechanism of action for treatment of AD.